Literature DB >> 316744

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

W E Evans, C B Pratt, R H Taylor, L F Barker, W R Crom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 316744     DOI： 10.1007/bf00262416

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  24 in total

1.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.

Authors:  P R Leme; P J Creaven; L M Allen; M Berman
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity.

Authors:  H M Pinedo; B A Chabner
Journal:  Cancer Treat Rep       Date:  1977-07

3.  High-dose methotrexate, not a conventional treatment.

Authors:  R Catane; V H Bono; A C Louie; F M Muggia
Journal:  Cancer Treat Rep       Date:  1978-01

4.  "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.

Authors:  D D Von Hoff; M Rozencweig; A C Louie; R A Bender; F M Muggia
Journal:  Cancer Treat Rep       Date:  1978-02

5.  "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.

Authors:  J R Bertino
Journal:  Semin Oncol       Date:  1977-06       Impact factor: 4.929

6.  Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults.

Authors:  B M Mehta; A L Gisolfi; D J Hutchison; A Nirenberg; M G Kellick; G Rosen
Journal:  Cancer Treat Rep       Date:  1978-03

7.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

8.  Methotrexate tissue distribution: prediction by a mathematical model.

Authors:  D S Zaharko; R L Dedrick; K B Bischoff; J A Longstreth; V T Oliverio
Journal:  J Natl Cancer Inst       Date:  1971-04       Impact factor: 13.506

9.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

10.  The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.

Authors:  H M Pinedo; D S Zaharko; J Bull; B A Chabner
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701
View more
  25 in total

1.  Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.

Authors:  Erin Dombrowsky; Bhuvana Jayaraman; Mahesh Narayan; Jeffrey S Barrett
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

2.  Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.

Authors:  M-A Estève; B Devictor-Pierre; G Galy; N André; C Coze; B Lacarelle; J-L Bernard; S Monjanel-Mouterde
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

3.  The utility of online haemodiafiltration in methotrexate poisoning.

Authors:  Mohamed Said Abdelsalam; Mohammed Mahdi Althaf; Osman Alfurayh; Irfan Maghfoor
Journal:  BMJ Case Rep       Date:  2014-05-23

4.  Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.

Authors:  Annick Rousseau; Christophe Sabot; Nicole Delepine; Gerard Delepine; Jean Debord; Gerard Lachâtre; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.

Authors:  H Schrøder; K B Jensen; M Brandsborg
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

9.  Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

Authors:  F Lokiec; O Poirier; C Gisselbrecht; M Marty; M Boiron; Y Najean
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.

Authors:  M Luyckx; J L Cazin; C Brunet; P Gosselin; M C Demaille
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.